Document:

Exhibit 10.1

 

THIRD AMENDMENT TO AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

THIS THIRD AMENDMENT
TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Third Amendment”) is entered into as of the 17th day of March, 2018
by and between Atrion Corporation, a Delaware corporation (the “Company”), and Emile A Battat (the “Executive”).

 

W I T N E S S E T H:

 

WHEREAS, the Company
and the Executive are currently parties to an Amended and Restated Employment Agreement dated as of the August 7, 2006 (the "Amended
and Restated Employment Agreement") that was amended by a First Amendment to Amended and Restated Employment Agreement dated
as of May 26, 2011 (the “First Amendment”) and by a Second Amendment to Amended and Restated Employment Agreement dated
as of May 24, 2016 (the “Second Amendment,” and the Amended and Restated Employment Agreement as amended by the First
Amendment and the Second Amendment being herein referred to as the “Employment Agreement”) pursuant to which the Executive
is employed by the Company until December 31, 2021; and

 

WHEREAS, the Company
and the Executive desire to amend the Employment Agreement to (a) change the provision setting forth how much advance notice of
non-renewal for any Additional Term (as defined in the Employment Agreement) is to be given, (b) include provisions addressing
the Executive’s retirement if it occurs during the Employment Term, and (c) delete the provisions of the Employment Agreement
that provide for a Gross-up Payment (as defined in the Employment Agreement) to the Executive in the event any of the payments
or benefits provided to the Executive are subject to the excise tax imposed by Section 4999 of the Code.

 

NOW, THEREFORE, in
consideration of the foregoing, the mutual provisions contained herein, and for other good and valuable consideration, the parties
hereto agree as follows:

 

1. CAPITALIZED TERMS. Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Employment
Agreement.

 

2. AMENDMENT TO SECTION 2 OF THE EMPLOYMENT AGREEMENT. The third
sentence of Section 2 of the Employment Agreement is amended by deleting the reference to “thirty (30) days” and substituting
in lieu and instead thereof “six (6) months.”

 

    1

     

    

 

3. RETIREMENT DURING EMPLOYMENT TERM.

 

(A) Section 4(c) shall be deleted in its entirety and the following
shall be substituted in lieu and instead thereof:

 

(c) Termination Upon Retirement,
Death, or Disability. The Executive's employment shall terminate immediately upon his Retirement
(as defined below) or his death. In the event that the Executive becomes subject to a Disability (as defined below), the Executive's
employment may be terminated upon thirty (30) days written notice by either party to the other.

 

 

(B)  Section 4(d) shall be revised by adding the following
as clause (iv):

 

(iv) Retirement. The term “Retirement”
shall mean voluntary termination of employment with the Company and its Subsidiaries after attaining the age of 65.

 

(C)  Section 4(e)(v) shall be modified by adding the word
“Retirement” in the heading thereof so that said Section 4(e)(v) shall state as follows:

 

(e)(v) Termination upon Retirement, Death,
or Disability. In the event the Executive's employment is terminated pursuant to Section 4(c) hereof, the Company shall
have no further obligation under Sections 3 and 4 of this Agreement except to pay to the Executive (or his personal representative
or guardian) a cash lump sum amount equal to the Accrued Amounts and

the Severance Payment, which shall be paid by
the Company as soon as practicable after the termination date, but in no event later than ten (10) days after the termination of
the Executive's employment. In addition, all stock options and/or equity granted to the Executive shall fully vest and become exercisable
upon the termination date. The Company shall also provide the Executive (and/or his spouse and dependents as applicable) with the
One Year Medical Benefits.

 

4. DELETION OF SECTION
9 OF THE EMPLOYMENT AGREEMENT. Section 9 of the Employment Agreement entitled “Excise Tax Gross-Up” is deleted in its
entirety.

 

5. FULL FORCE AND EFFECT.
Except as specifically amended herein, all other terms and conditions in the Employment Agreement shall remain unchanged and shall
continue in full force and effect. From and after the date of this Third Amendment, any and all references to the Employment Agreement
shall refer to the Employment Agreement as hereby amended.

 

6. MULTIPLE COUNTERPARTS.
This Third Amendment may be executed in counterparts, each of which for all purposes is to be deemed an original, and both of which
constitute, collectively, one agreement, but in making proof of this Third Amendment, it shall not be necessary to produce or account
for more than one such counterpart.

 

 

 

[Signatures appear on following page.]

 

    2

     

    

 

 

IN WITNESS WHEREOF,
the parties have caused this Third Amendment to be duly executed and delivered as of the date first above written.

 

 

 

	 	ATRION CORPORATION
	 	 
	 	By: 	/s/ David A. Battat
	 	 	David A. Battat
President and Chief Executive Officer
	 	 	 
	 	 	 
	 	 
	 	/s/ Emile Battat
	 	EMILE A BATTAT
	 	 
	 	 	 

 

    3Exhibit 4.15

 

	
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

	
1. CONTRACT ID CODE

	
PAGE OF PAGES 

	 	 	
1

	
4

	
2. AMENDMENT/MODIFICATION NO. 

0004

	
3. EFFECTIVE DATE

07/09/2017

	
4. REQUISITION/PURCHASE REQ. NO. 

OS201369

	
5. PROJECT NO. (If applicable)

	
6. ISSUED BY  

	CODE    	
ASPR-BARDA

	
7. ADMINISTERED BY (If other than Item 6)

	
CODE   

	ASPR-BARDA01 
	
ASPR-BARDA

200 Independence Ave., S.W. 

Room 640-G 

Washington DC 20201

 

	
 

	
ASPR-BARDA

330 Independence Ave, SW, Rm G644 

Washington DC 20201

	
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

	
(x)

	
9A. AMENDMENT OF SOLICITATION NO.

	
 

MEDIWOUND LTD 1477616

	 	 
	
MEDIWOUND LTD          42 HAYARKON

42 HAYARKON

	 	
9B. DATED (SEE ITEM 11)

	
YAVNE    00812

 	
X

	
10A. MODIFICATION OF CONTRACT/ORDER NO.

HHSO100201500035C

 

	 	 	
10B. DATED (SEE ITEM 13)

	
CODE    1477616

	
FACILITY CODE

	 	
09/29/2015

	
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	
☐

	
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers   ☐ is extended.      ☐ is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning ________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which indudes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER If by virtue of this amendment you desire to change an offer already submitted. such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	
12. ACCOUNTING AND APPROPRIATION DATA (If required)

 See Schedule

	
Net Increase:

	
$31,665,598.00

	
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

 

	
CHECK ONE

	
A.   THE CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	
 

	
 

	
B.    THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). 

	
X

	
C.    THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: 

FAR 1.602-1 and Mutual Agreement of All Parties, FAR Changes Clauses Sections 52.243-02

	
 

	
D.    OTHER (Specify type of modification and authority)

 

	
E. IMPORTANT:

	
Contractor

	
☐is not. 

	
☒is required to sign this document and return          2   copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number:   C0-0000387

DUNS Number:   532040334

PURPOSE of this modification is to:

 

a) Add supplemental funds to CLIN 0001 changing the value from $23,955, 661 to $30, 176, 634

 

b) Change the amount of optional CLIN 0004A from $11,925,619 to $25,444,625 and exercise said optional CLIN 0004A.

 

The changes will increase the amount obligated under the contract by $31,665,598 

 

Continued ...

 

	
Except as provided herein, all terms and conditions  of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect

	
15A. NAME AND TITLE OF SIGNER (Type or print)

 

GAL COHEN-CEO, SHARON MALKA - CFO

	
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

 

SALIM K. ROBERTS

	
15B. CONTRACTOR/OFFEROR

	
15C. DATE SIGNED

 

 

 

 

 

July 16, 2017

	
16B. UNITED STATES OF AMERICA

	
16C. DATE SIGNED

 

 

 

 

 

    17JUL2017

	 	 
	
(Signature of person authorized to sign)

	
(Signature of Contracting Officer)

	
NSN7540-01-152-8070 

Previous edition unusable

	
STANDARD FORM 30 (REV, 10-83) 

 Prescribed by GSA 

FAR (48 CFR) 53.243

	
CONTINUATION SHEET

	
REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201500035C/0004

	
PAGE      OF

	 	 	
2

	
4

NAME OF OFFEROR OR CONTRACTOR

MEDIWOUND LTD 1477 616

	
ITEM NO.

 (A)

 

	
SUPPLIES/SERVICES

 (B)

	 	
QUANTITY

 (C)

	
UNIT

 (D)

	
UNIT PRICE

 (E)

	
AMOUNT

 (F)

	 	
Funds Obligated Prior to this Modification

	
$40,430,469

	
 

	 	 	
	 	
Funds Obligated with mod #04

	
$31,665,598

	
 

	 	 	
	 	
Total Funds Obligated to Date

	
$72,096,067

	
 

	 	 	
	 	
 

	 	 	 	 	 
	 	
Expiration date: 

	July 31, 2023	
 

	 	 	 
	 	
(Please see Continuation Sheet)

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
Except as provided herein, all terms and conditions of thecontract remains unchanged Delivery Location Code: HHS/OS/ASPR

	 	 	 	 	 
	 	
HHS/OS/ASPR

	 	 	 	 	 
	 	
200 C St SW

	 	 	 	 	 
	 	
WASHINGTON DC 20201 US

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
FOB: Destination

	 	 	 	 	 
	 	
Period of Performance: 09/29/2015 to 07/31/2023

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
Change Item 1 to read as follows (amount shown is the obligated amount):

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	
1

	
ASPR-15-08828 -- CLIN 0001 Advanced development 

	 	 	 	 	
6,220,973.00

	 	
studies for NexoBrid

	 	 	 	 	 
	 	
Obligated Amount: $6,220,973.00

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
Delivery: 10/05/2015

	 	 	 	 	 
	 	
Amount: $23,955,661.00

	 	 	 	 	 
	 	
Accounting Info:

	 	 	 	 	 
	 	
2015.1990002.26201 Appr. Yr.: 2015 CAN: 1990002 Object Class : 26201 

	 	 	 	 	 
	 	
Funded: $0.00

	 	 	 	 	 
	 	 	 	 	 	 	 
	 	
Delivery: 07/10/2017

	 	 	 	 	 
	 	
Amount: $6,220,973.00

	 	 	 	 	 
	 	
Accounting Info:

	 	 	 	 	 
	 	
2017.1990007.25106 Appr. Yr.: 2017 CAN: 1990007 Object Class : 25106 

	 	 	 	 	 
	 	
Funded: $6,220,973.00

	 	 	 	 	 
	 	 	 	 	 	 	 
	 	
Change Item 4 to read as follows (amount shown is the obligated amount):

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	
4

	
CLIN--0004A Pediatric Study

	 	 	 	 	
25,444,625.00

	 	
Obligated Amount: $25,444,625.00

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
Delivery: 07/10/2017

	 	 	 	 	 
	 	
Amount: $16,903,548.48

	 	 	 	 	 
	 	
Accounting Info:

	 	 	 	 	 
	 	
2017.1990007.25106 Appr. Yr.: 2017 CAN: 1990007 Object Class : 25106

	 	 	 	 	 
	 	
Funded: $16,903,548.48

	 	 	 	 	 
	 	
 

	 	 	 	 	 
	 	
Delivery: 07/10/2017

	 	 	 	 	 
	 	
Amount: $8,541,076.52

	 	 	 	 	 
	 	
Accounting Info:

	 	 	 	 	 
	 	
Continued...

	 	 	 	 	 
	 	 	 	 	 	 	 

 

	
NSN 7540-01-152-8067

	 	
OPTIONAL FORM 336 (4-86)

	 	 	 	
Sponsored by GSA

	 	 	 	
FAR (48 CFR) 53.110

 

	
CONTINUATION SHEET

	
REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201500035C/0004

	
PAGE      OF

	 	 	
3

	
4

NAME OF OFFEROR OR CONTRACTOR

MEDIWOUND LTD 1477 616

	
ITEM NO.

 (A)

	
SUPPLIES/SERVICES

 (B)

	
QUANTITY

 (C)

	
UNIT

 (D)

	
UNIT PRICE

 (E)

	
AMOUNT 

 (F)

	 	
2017.1990008.25106 Appr. Yr.: 2017 CAN: 1990008 Object Class : 25106 

	 	 	 	 
	 	
Funded: $8,541,076.52

	 	 	 	 
	 	 	 	 	 	 

	
NSN 7540-01-152-8067

	 	
OPTIONAL FORM 336 (4-86)

	 	 	 	
Sponsored by GSA

	 	 	 	
FAR (48 CFR) 53.110

 

	
Contract Number HHSO100201500035C 

 Modification No: 04

	 	
page 4 of 4

 

	 	 	
(Continuation Sheet)

	
Continuation Sheet

	
 

Contract No: HHSO100201500035C 

 Modification No: 04

 

	 

 

The purpose of this Modification is to:

 

	
A.

	
ADD SUPPLEMENTAL FUNDS TO BASE CLIN 0001

 

	
B.

	
EXERCISE OPTIONAL CLIN 0004(A)

 

The contract is revised as follows to:

 

	
1.

	
Amend CLIN 0001 and provide additional funding in the amount of $6,220,974 to bring the total to $30,176,634

	
2.

	
Exercise optional CLIN 0004(A) and provide funding in the amount of $25,444,625 for the CLIN 0004(A).

	
3.

	
Update Sections F.1 requirements to extend the period of performance for CLIN 00004(A) to July 31, 2023.

	
4.

	
Update Section B.3 in accordance with Contractor’s proposal dated May 16, 2017 by replacing the CLIN 0001 and CLIN 0004(A) tables with the table below :

 

	
CLIN

	
Period of 

 Performance

	
Supplies/Services

	
Total Est. Cost

	
Fixed Fee

(7%)

	
Total Cost Plus Fixed Fee

	
CLIN 0001

	
09/28/2015- 06/30/2021

	
Licensure, approval, and clearance of product through the FDA

	
$28,486,743

	
$1,689,891

	
$30,176,634 (Funded)

	 	 	 	 	 	 
	
CLIN 0004(A)

	
08/01/2017- 07/31/23

	
Pediatric Study (This is an option that may or may not be exercised during the base period for expansion of the label indication with guidance from the FDA)

	
$23,989,225

	
$1,455,400

	
$25,444,625 (Funded)

 

Total value of Contract before MOD 04 is $40,430,469 

 

Total value of Contract after MOD 04 is $72,096,067

 

All other terms and conditions of the contract HHSO201500035C remain unchanged.

 

[End of Modification No. 04 and the remainder of this page intentionally left blank]

 

	
Contract Number HHSO100201500035C

	
Page 4 of 4

	
Modification No: 04

	
 

	 	
(Continuation Sheet)

 

	
Continuation Sheet

	
 

Contract No: HHSO100201500035C 

Modification No: 04

 

	 

 

The purpose of this Modification is to:

 

	
A.

	
ADD SUPPLEMENTAL FUNDS TO BASE CLIN 0001

 

	
B.

	
EXERCISE OPTIONAL CLIN 0004(A)

 

The contract is revised as follows to:

	
1.

	
Amend CLIN 0001 and provide additional funding in the amount of $6,220,974 to bring the total to $30,176,634

	
2.

	
Exercise optional CLIN 0004(A) and provide funding in the amount of $25,444,625 for the CLIN 0004(A).

	
3.

	
Update Sections F.1 requirements to extend the period of performance for CLIN 00004(A) to July 31, 2023.

	
4.

	
Update Section B.3 in accordance with Contractor’s proposal dated May16, 2017 by replacing the CLIN 0001and CLIN 0004(A) tables with the table below :

 

	
CLIN

	
Period of 

Performance

	
Supplies/Services

	
Total Est. Cost

	
Fixed Fee

(7%)

	
Total Cost Plus 

Fixed Fee

	
CLIN 0001

	
09/28/2015-06/30/2021

	
Licensure, approval, and clearance of product through the FDA

	
$28,486,743

	
$1,689,891

	
$30,176,634 (Funded)

	 	 	 	 	 	 
	
CLIN 0004(A)

	
08/01/2017-07/31/23

 

	
Pediatric Study

	
$23,989,225

	
$1,455,400

	
$25,444,625 (Funded)

 

Total value of Contract before MOD 04 is $40,430,469

 

Total value of Contract after MOD 04 is $72,096,067

All other terms and conditions of the contract HHSO201500035C remain unchanged.

 

[End of Modification No. 04 and the remainder of this page intentionally left blank]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]